Abstract
Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition. Thirty-eight patients initially received Trilostane of whom 19 subsequently received Aminoglutethimide; 34 patients initially had Aminoglutethimide and seven of these then received Trilostane. Both groups of patients were comparable in all respects. There was no difference in the objective response rate to either drug, Trilostane 11/38 = 29%, Aminoglutethimide 12/34 = 35%, nor in the average time to disease progression for the two drugs, Trilostane 64 weeks, Aminoglutethimide 68 weeks. Of the 26 patients who received both drugs, four showed a response to both suggesting no cross resistance. Side effects were seen to both drugs in approximately half of the patients, but were mainly gastro-intestinal with Trilostane and rash and drowsiness with Aminoglutethimide. There was no evidence of cross over patient susceptibility to side effects.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beardwell C. G., Hindley A. C., Wilkinson P. M., St John J., Bu'lock D. Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. Clin Endocrinol (Oxf) 1985 Oct;23(4):413–421. doi: 10.1111/j.1365-2265.1985.tb01099.x. [DOI] [PubMed] [Google Scholar]
- Beardwell C. G., Hindley A. C., Wilkinson P. M., Todd I. D., Ribeiro G. G., Bu'Lock D. Trilostane in the treatment of advanced breast cancer. Cancer Chemother Pharmacol. 1983;10(3):158–160. doi: 10.1007/BF00255752. [DOI] [PubMed] [Google Scholar]
- Hayward J. L., Carbone P. P., Heusen J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. doi: 10.1038/bjc.1977.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lawrence B. V., Lipton A., Harvey H. A., Santen R. J., Wells S. A., Jr, Cox C. E., White D. S., Smart E. K. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer. 1980 Feb 15;45(4):786–791. doi: 10.1002/1097-0142(19800215)45:4<786::aid-cncr2820450429>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
- Santen R. J., Misbin R. I. Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy. 1981 Sep-Oct;1(2):95–120. doi: 10.1002/j.1875-9114.1981.tb03557.x. [DOI] [PubMed] [Google Scholar]
- Tueni E., Devleeschouwer N., Leclercq G., Nijs M., Coune A., Vermeulen A., Paridaens R. Endocrine effects of Trilostane: in vitro and in vivo studies. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1461–1467. doi: 10.1016/0277-5379(87)90087-3. [DOI] [PubMed] [Google Scholar]
- Vermeulen A., Paridaens R., Heuson J. C. Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol (Oxf) 1983 Dec;19(6):673–682. doi: 10.1111/j.1365-2265.1983.tb00044.x. [DOI] [PubMed] [Google Scholar]
- Williams C. J., Barley V., Blackledge G., Hutcheon A., Kaye S., Smith D., Keen C., Webster D. J., Rowland C., Tyrrell C. Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep. 1987 Dec;71(12):1197–1201. [PubMed] [Google Scholar]